HeartWare International — Shareholder Meeting (July 2008)
16 slides from HeartWare International's shareholder meeting presentation, Jul 10, 2008
Slide 1: Corporate Update - Extraordinary General Meeting
HeartWare Limited (ASX:HTW) » David McIntyre Chief Financial Officer Extraordinary General Meeting 11 July 2008 » Corporate Update
Slide 2: Topics
Topics Market Opportunity Recap Business Updates International Clinical Trial US Clinical Trial Pipeline Products Upcoming Milestones
Slide 3: Heart Failure is a significant problem for society
Heart Failure is a significant problem for society A degenerative and terminal disease Affects over 20 million people globally (5+ million in the US) 1 million new cases diagnosed every year 300,000 deaths per year in the US At least 1 million patients in NYHA Class IV, the end-stage of the disease
Slide 4: LVAD's are the only viable option for most
LVAD's are the only viable option for most Heart transplantation is a proven therapy, but availability is severely limited Fewer than 4,000 donor hearts annually Many patients ineligible for transplantation Alternative therapies not delivering on initial promise Drugs & pacing do not halt disease pr
Slide 5: The HeartWare Left Ventricular Assist System
The HeartWare Left Ventricular Assist System Miniaturized implantable blood pump (50cc / 140g) The only centrifugal pump designed to be implanted in the chest, directly adjacent to the heart Capable of producing up to 10 L/Min of flow Only one moving part Hybrid magnetic / hydrodynamic suspension me
Slide 6: Pericardial placement - a key differentiator
Reprinted with permission from Thoratec Corporation Pericardial placement - a key differentiator Abdominal (Others) Pericardial (HeartWare) No abdominal surgery No pump pocket drains No pump pocket infections No GI distress related to abdominal organ pressure Reduced procedural invasiveness and comp
Slide 7: International clinical trial - overview
International clinical trial - overview Trial enrolment completed August 2007 (20 patients) Extension approved to allow up to 50 patients Primary endpoint is survival to 180 days or transplant Submission of Technical Dossier expected Q3 2008, CE mark anticipated Q4 2008
Slide 8: International clinical trial - status update
Dr George Wieselthaler, Principal Investigator at Vienna General Hospital, with three of his HeartWare patients 40 patients enrolled to date Cumulative support - approx 9,000 days (24+ yrs) Average support - 225 days per patient >91% survival (of first 28 patients, 26 have successfully passed trial
Slide 9: International clinical trial - data for first patients presented at ISHLT
International clinical trial - data for first 23 patients presented at ISHLT *Presented by G Wieselthaler, MD at the ISHLT Annual Meeting, Boston, MA, April 12, 2008 At 180 days: Survival - 91% Transplant- 10% Recovery - 0% Death - 9%
Slide 10: US clinical trial - overview
US clinical trial - overview Received conditional approval for BTT protocol on 1 May 2008 No safety phase required; directly to pivotal 150 patients at a maximum 28 centers Utilizing NIH funded control arm (Intermacs Registry) Immediate patient discharge permitted Expect first patient July / August
Slide 11: US clinical trial - initial sites
Finalizing clinical trial contract arrangements with 10+ lead centres CMS reimbursement running in parallel Very few remaining conditions with conditional IDE 3 sites trained 4 additional sites scheduled for training over next 6 weeks US clinical trial - initial sites
Slide 12: Product pipeline - pump miniaturization
Product pipeline - pump miniaturization Procedure Surgical Minimally Invasive Catheter Delivery System Flow 10 L/min 7 L/min 3 L/min Patient Class Late Class IV Class III & IV Class III Treatable Pop. 100,000 350,000 1,000,000 Current status: IDE Preclinical studies Prototype and exploratory HVADTM
Slide 13: MVAD showing promise and versatility
MVAD showing promise and versatility Developing implant techniques that avoid sternotomy MVAD seems to work wherever we place it Goals are Small incision Decrease complications Increase number of patients who can benefit Will select "winner" in 2008 Full project kick off in 2009 First human implant
Slide 14: Product pipeline - TET System
Transcutaneous Energy Transfer showing significant progress Enables transfer of energy and information across the skin Replaces driveline cable and eliminates risk of driveline complications Enables patient to be un-tethered from the charging system for extended periods Successfully demonstrated fea
Slide 15: Key Milestones
Key Milestones Milestone Timing Status Submissions of IDE to US FDA Q4 2007 Extension of International Trial to allow additional implants Q4 2007 Approval to Commence US trial Capital raising Commission new manufacturing facility Q2 2008 Q2 2008 Q3 2008 On Target Submission of Technical Dossier to C
Slide 16: Thank You
Thank You